Skip to main
TIL

Instil Bio (TIL) Stock Forecast & Price Target

Instil Bio (TIL) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Instil Bio Inc's focus on developing a unique pipeline of autologous tumor infiltrating lymphocyte therapies, including the CoStAR platform, positions it well within the evolving oncology landscape. The potential of its ITIL-306 therapy, which targets a tumor-associated antigen prevalent in various solid tumors, underscores the company's innovative approach and expands its therapeutic reach. Furthermore, the anticipated positive updates from related therapeutic classes may enhance investor sentiment, creating a favorable environment for Instil Bio's continued growth and valuation upside.

Bears say

Instil Bio Inc's stock outlook has been negatively impacted by the discontinuation of AXN-2510, which was a core value driver, necessitating a comprehensive reassessment of the company's financial thesis. There are significant risks associated with potential delays in advancing clinical candidates, the failure to produce positive clinical data, and concerns over medium- to long-term dilution, all contributing to investor uncertainty. The absence of strategic clarity has positioned the stock as lacking momentum in the short term, with its enterprise value trading slightly below cash levels, highlighting the challenging financial circumstances the company faces.

Instil Bio (TIL) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Instil Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Instil Bio (TIL) Forecast

Analysts have given Instil Bio (TIL) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Instil Bio (TIL) has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $125, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $125, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Instil Bio (TIL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.